Increased mean platelet volume (MPV) has been associated with adverse clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). We aim to assess whether MPV/platelet count (MPV/PC) ratio is a useful marker to predict long-term prognosis in patients with STEMI undergoing PCI. Moreover, the prognostic accuracy of MPV/PC ratio is compared with MPV. 962 consecutive patients with STEMI treated with P-PCI were considered. According to the admission MPV/PC values, the population was divided into two groups: high MPV/PC group (n = 320, MPV/PC !0.055) and low MPV/PC group (n = 642, MPV/PC < 0.055). Multivariate analysis showed that high MPV/PC was an independent predictor of major adverse cardiovascular event (MACE; hazard ratio [HR]: 1.121, 95% confidence interval [CI]: 1.056-1.190, P < 0.01), all-cause mortality (HR: 1.109, 95% CI: 1.016-1.209, P = 0.020), cardiac mortality (HR: 1.141, 95% CI: 1.038-1.253, P = 0.006), nonfatal myocardial reinfarction (HR: 1.148, 95% CI: 1.044-1.262, P = 0.004), and unplanned repeat revascularization (HR: 1.073, 95% CI: 1.007-1.144, P = 0.030), respectively. MPV/PC ratio has good accuracy for predicting MACE (the area under the receiver-operating characteristic curve: 0.764), and the cut-off value was 0.054 with a sensitivity of 0.813 and a specificity of 0.662. The discriminatory performance of MPV/PC ratio was better than MPV for predicting MACE (MPV/PC ratio versus MPV: z = 2.285, P = 0.022), in patients with STEMI undergoing P-PCI. MPV/PC ratio is able to but better than MPV to predict long-term adverse outcomes in patients with STEMI undergoing P-PCI. (Int Heart J 2018; 59: 286-292) 
T he prognosis of patients with ST-segment elevation myocardial infarction (STEMI) is bad, even receiving primary percutaneous coronary intervention (P-PCI). 1) Inflammatory and thrombosis play important roles in the adverse prognosis of patients with STEMI. 2, 3) Inappropriate platelet activation is a key element of the coronary thrombosis in patients with STEMI. 4) Moreover, it plays a critical role in stent thrombosis of patients with partially endothelialized intracoronary stents following PCI. 5) Larger platelets are more thrombogenic and active than smaller ones, 6, 7) so mean platelet volume (MPV), as a parameter of platelet volume, is an important biomarker to assess platelet activation. 6, 8) Increased MPV was confirmed to be related with coronary artery disease (CAD). 9) Further, recent researches have shown that increased MPV was associated with a worse short-term [10] [11] [12] [13] [14] and long-term 11, [15] [16] [17] prognosis, as well as angiographic thrombus burden 13) and impaired myocardial reperfusion 12, 14, 15) in patients with STEMI undergoing P-PCI. And platelet count (PC) has been determined as an important predictor of adverse events in patients with CAD undergoing PCI. 18, 19) There is an inverse relation of MPV and PC in patients with acute coronary syndrome. 20) Consequently, integration of MPV and PC as a ratio is necessary and possible. MPV/PC ratio has been found to be superior to the MPV alone in predicting long-term mortality after non-ST-segment elevation myocardial infarction (NSTEMI). 21) MPV/PC ratio was also a predictor of adverse outcome in patients with STEMI undergoing P-PCI. 22) However, superior of MPV/PC ratio than MPV has not been studied so far in patients with STEMI undergoing P-PCI.
Methods
Study design and setting: This study was based on a retrospective observational cohort that has been previously described. 23) In brief, from January 1, 2010 to October 31, 2014, 3,007 consecutive acute coronary syndrome patients, who were hospitalized and underwent PCI at a large-scale hospital in Northeast China (Shengjing Hospital of China Medical University, Shenyang, China), were included in the cohort. Clinical data and procedural data of all cases were gained by the investigators from electronic medical records, Picture Archiving and Communication Systems of the interventional imaging data, and operation records of PCI cases. This study only included 1,080 patients with STEMI in the cohort. Killip classification was previously introduced. 24) In all cases, venous blood samples were drawn on admission in standard tubes containing dipotassium ethylenedinitro tetraacetic acid (EDTA) at room temperature; the samples were tested within 120 minutes of blood collection. 25) MPV and PC were included in complete blood counts and measured by an automated blood counter (UniCel DxH800 Coulter , Beckman Coulter Corp, Hialeah, FL, USA) using optical light scatter counting in the core laboratory of Shengjing Hospital. Left ventricular ejection fraction (LVEF) was determined during hospitalization by echocardiography. Procedural data came from operation records of PCI cases finished by operators. Angiographic variables were visually or quantitative computer analysis system estimated. Thrombolysis in myocardial infarction flow grade was determined as defined previously. 26) Clinical follow-up was assessed in October 2015 by direct hospital visits or phone interviews of patient's general practitioner/cardiologist, patient himself, or his family. All patients were followed for a mean duration of 30 months (12-68 months). All events were identified from the patients' medical records or the patient's referring hospital physician, and validated by two independent event-judge physicians. This study complies with the Declaration of Helsinki, and Shengjing Hospital of China Medical University Research Ethics Committee approved the research protocol. Written informed consent was formally obtained from all participants. Participants and procedures: We identified 1,080 patients with STEMI treated with P-PCI. To be eligible for P-PCI, patients must meet the following criteria: (1) chest pain present less than 12 hours from onset of pain to time of catheterization, (2) significant ST-segment elevation (at least 0.1 mV in two or more standard leads or at least 0.2 mV in two or more contiguous precordial leads) or a new left bundle branch block. After confirmation of STEMI, P-PCI was urgently undertaken according to current guideline recommendations and operators' routine practice. Operators decided the use of aspiration thrombectomy, heparin, or glycoprotein IIb/IIIa inhibitor. The culprit artery was determined with ECG, echocardiography, and angiographic findings by each operator. Exclusion criteria included (1) treatment with a fibrinolytic agent within the previous 24 hours, (2) hematoproliferative disorders, (3) culprit PCI failed, (4) autoimmune diseases or steroid therapy, (5) active infection, (6) end-stage liver or renal failure, and (7) no complete blood count available. The final study cohort consisted of 962 patients. After the determination of baseline MPV/PC values, the final study population was divided into tertiles (first tertile: < 0.041 [n = 313]; second tertile: 0.041-0.055 [n = 329]; third tertile: !0.055 [n = 320]). A high MPV/PC (n = 320) was defined as a value in the third tertile (!0.055), and a low MPV/PC (n = 642) was defined as a value in the lower two tertiles (< 0.055). Periprocedural and postprocedural antiplatelet treatments and other cardiovascular medications were given in accordance with current guidelines. 24) Clinical end points: Primary end point was major adverse cardiovascular events (MACEs), a composite of cardiac mortality and nonfatal reinfarction. Secondary end points were all-cause mortality, cardiac mortality, nonfatal myocardial reinfarction, and unplanned repeat revascularization, which included any unplanned repeat PCI or surgical bypass of target or nontarget vessels. Statistical analysis: Quantitative variables were represented as mean ± standard deviation or median (interquartile range) and compared with independent samples t-test or Mann-Whitney U-test. Categorical variables were represented as counts and proportions (%) and compared with chi-square test. Cox proportional-hazard regression modeling was used to analyze the effect of variables on eventfree survival. The variables that showed significances in univariate analysis between the two groups (P < 0.05) were "entered" into the model (Table I) . Results were reported as hazard ratios with associated 95% confidence intervals (CIs). The accuracy of MPV/PC and MPV for predicting MACE was assessed according to the area under the receiver-operating characteristic curve (ROC-AUC) 27 ) and compared using a nonparametric test developed by DeLong, et al. 28) with the use of MedCalc software for Windows, version 11.4.2.0 (MedCalc Software, Mariakerke, Belgium). AUC values > 0.5, 0.75, and 0.93 were considered as fair, good, and very good accuracy. 29) All tests were two sided, and the statistical significance was defined as P < 0.05. All statistical analyses were performed with the use of SPSS version 19 (SPSS Inc., Chicago, Illinois, USA).
Results
Participants: Between January 1, 2010, and October 1, 2014, a total of 1,080 patients were treated with P-PCI for STEMI in our cohort. Figure 1 presents the flowchart for patient selection. The final study cohort consisted of 962 patients, of whom 642 in the low MPV/PC ratio group and 320 in the high MPV/PC ratio group.
Baseline clinical characteristics and periprocedural details were listed in Table II . Patients with high MPV/PC ratio were older and had significantly lower LVEF, creatinine, hemoglobin, leukocyte count, lymphocyte, neutrophil, platelet, the rate of use of glycoprotein IIb/IIIa inhibitor, and higher MPV compared with those with low MPV/PC ratio (Table II) . The rates of three-vessel disease and intra-aortic balloon pump use were found to be significantly higher in the high MPV/PC group (Table II) . Discharge medication was similar between two groups (Table II) . Clinical outcome: During the follow-up, there were 48 events of MACE, 30 events of all-cause mortality, 25 events of cardiac mortality, 23 events of nonfatal myocardial reinfarction, and 59 events of unplanned repeat revascularization in the whole study cohort. The rates of MACE, all-cause mortality, cardiac mortality, nonfatal myocardial reinfarction, and unplanned repeat revasculari-Tian, ET AL zation were significantly higher in patients with high MPV/PC ratio compared with those with low MPV/PC ratio (9.4% versus 2.8%, P < 0.001; 5.9% versus 1.7%, < 0.001; 5.3% versus 1.2%, P < 0.001; 4.0% versus 1.6%, P = 0.017; 8.4% versus 5.0%, P = 0.035, respectively).
MPV/PC RATIO PREDICATE PROGNOSIS IN STEMI
After adjusting for covariates, high MPV/PC remained an independent predictor of MACE, all-cause mortality, cardiac mortality, nonfatal myocardial reinfarction, and unplanned repeat revascularization; high MPV was an independent predictor of MACE, all-cause mortality, cardiac mortality, and nonfatal myocardial reinfarction, respectively (Table I) . PC was not significantly associated with long-term prognosis (Table I) . Prognostic accuracy and comparison of different parameters: The ROC-AUC of MPV/PC ratio and MPV for predicting MACE was 0.764 and 0.679, respectively (Table III and Figure 2) . The discriminatory performance of MPV/PC ratio was better than MPV for predicting MACE (MPV/P ratio versus MPV: z = 2.285, P = 0.022; Table  III ). The cut-off value for MPV/PC ratio for the prediction of MACE was 0.054 with a ROC-AUC of 0.764 (95% CI 0.698-0.830), a sensitivity of 0.813 and a specificity of 0.662.
Discussion
Our study tested the predictive value of MPV/PC ratio for the long-term prognosis in patients with STEMI undergoing P-PCI. The main findings were as follows: (1) Tian, ET AL Figure 2 . Receiver-operating characteristic curves of MPV/P ratio and MPV for MACE prediction.
high MPV/PC was an independent predictor of MACE, all-cause mortality, cardiac mortality, nonfatal myocardial reinfarction, and unplanned repeat revascularization; (2) MPV/PC ratio has good accuracy for predicting MACE, and the cut-off value was 0.054 with a sensitivity of 0.813 and a specificity of 0.662; and (3) the discriminatory performance of MPV/PC ratio was better than MPV for predicting MACE, in patients with STEMI undergoing P-PCI. Huczek, et al. took the lead in the study of the prognostic value of MPV for the prognosis in patients with STEMI undergoing PCI. 15) They noted that MPV was a strong, independent predictor of impaired angiographic reperfusion and 6-month mortality in patients with STEMI undergoing PCI. 15) This observation has since been confirmed by several other studies [10] [11] [12] [13] [14] 16, 17) and has been extended by the observation that elevated MPV at admission was an independent predictor of large intracoronary thrombus burden.
13) The nature of such an association could be explained by the theory, that MPV reflects more thrombogenic and active platelets 6, 7) and is a link between thrombosis and inflammation. 30) Although the pooled analysis of four ISAR trials 19) and a subgroup analysis of the CADILLAC trial 18) confirmed that a higher baseline PC was a predictor of adverse prognosis in patients undergoing PCI, other studies found no significant association between baseline PC and adverse prognosis in patients with STEMI undergoing PCI. [11] [12] [13] [14] 22) Our study confirmed again that high MPV was an independent predictor of adverse prognosis for patients with STEMI undergoing P-PCI, but high PC was not.
O'Brienno, et al. found that the PC and MPV were inversely related in 1974. 31) Then other studies still found the inversed relationship exists in patients with acute coronary syndrome. 20) Subsequently, MPV and PC were interpreted as a ratio rather than as independent variables to predict the prognosis of patients with CAD. 21, 22) MPV/PC ratio has been found to be a predictor of adverse outcome in patients with STEMI or NSTEMI. 21, 22) Our study also found that high MPV/PC was an independent predictor of long-term adverse prognosis for patients with STEMI undergoing P-PCI. Furthermore, in our study, MPV/PC ratio was proven to have good accuracy for predicting MACE. More importantly, further analysis found that MPV/PC ratio deserved the better discriminatory performance than MPV for predicting MACE in patients with STEMI undergoing P-PCI. The possible biological function for our finding may be as follows: higher MPV/PC ratio means higher MPV and lower PC; higher MPV reflects more thrombogenic and active platelets 6, 7) and more severe inflammatory reactions; 30) lower PC related to higher expression of glycoprotein VI and inflammatory biomarkers in patients with acute coronary syndrome. 32, 33) Considering these results presented, and the fact that MPV and PC are easily, cheaply, and routinely assessed parameters of a complete blood count, it is worth emphasizing the prognostic impact of MPV/PC ratio. Limitations: This study had several limitations. First, this study was retrospective and observational, so potential confounders and selection bias could not be completely adjusted. Second, a standard method for the measurement of MPV, that includes the storage temperature of samples, the choice of anticoagulant, time interval from sampling to measurement, and technique implemented, has not been developed and adopted. Our study presents the value of MPV in "real world." In our hospital, standardized EDTA tubes and less than 2-hour time interval from sampling to measurement are used for the blood collection for a complete blood count in our core laboratory. Third, our study did not measure known inflammatory markers such as Creactive protein and erythrocyte sedimentation rate. Fourth, there is the lack of measurement of platelet function tests such as thrombelastograph. Fifth, we did not analyze in-hospital changes in MPV or PC because of the lack of data although an early increase in MPV and a severe decline in PC after admission were independently associated with adverse outcomes in patients with PCI 34, 35) . At last, the previous study found that dual antiplatelet therapy did not influence MPV in patients with CAD undergoing PCI. 36) However, whether MPV/PC and the prognosis are changeable by dual antiplatelet therapy is still unknown. In the future, a new study should be performed to obtain the conclusion.
Conclusion
High MPV/PC ratio was an independent predictor of long-term adverse prognosis in patients with STEMI undergoing P-PCI. Meanwhile, there is the significant superiority of MPV/PC ratio to MPV alone in predicting longterm cardiac mortality and nonfatal reinfarction.
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